# The Genetic Basis of Cancer: Mutations, Drivers, and Pathways

## Introduction to the Genetic Basis of Cancer

Cancer is fundamentally a genetic disease. This statement does not mean that all cancers are inherited; rather, it means that every cancer arises from alterations in the DNA sequence or chromatin structure of a single somatic cell. These alterations, collectively termed mutations, confer a growth advantage that allows the mutated cell and its progeny to proliferate abnormally, invade surrounding tissues, and eventually metastasize to distant organs.

The genetic basis of cancer rests on two core principles. First, cancer develops through the accumulation of multiple mutations over time, not through a single catastrophic event. Second, these mutations occur in somatic cells—cells of the body other than germ cells—and are therefore not transmitted to offspring unless they happen to arise in germline tissue. The process by which a single mutated cell expands into a tumor is called clonal evolution. As cells divide, they acquire new mutations; those that provide a selective advantage—such as faster growth, resistance to apoptosis, or the ability to invade—become dominant within the tumor population. This Darwinian selection at the cellular level explains why tumors become increasingly aggressive and heterogeneous over time.

### Cancer as a Multistep Process

The multistep nature of cancer was first formalized in the 1990s through studies of colorectal cancer, where distinct histopathological stages correlate with specific genetic alterations. A typical colorectal tumor begins as a hyperproliferative epithelium, progresses to an adenoma (benign polyp), then to a carcinoma, and finally to metastatic disease. Each step is associated with particular mutations: activation of the *KRAS* oncogene, inactivation of the *APC* tumor suppressor, and loss of *TP53*, among others. This model illustrates that tumorigenesis requires multiple "hits" affecting different genes and pathways.

Quantitatively, most adult solid tumors harbor between 30 and 100 non-silent mutations in protein-coding regions, though only a small fraction of these—typically 2 to 8—are "drivers" that actively promote cancer. The remainder are "passengers" that accumulated incidentally during cell division. The time required to acquire these mutations explains why cancer incidence rises sharply with age; the accumulation of mutations is a stochastic process that takes decades.

### Inherited vs. Somatic Mutations

It is essential to distinguish between germline and somatic mutations. Germline mutations are present in every cell of an individual's body because they arose in the egg or sperm or during early embryonic development. These mutations are inherited and account for the familial clustering seen in certain cancers. However, germline mutations alone rarely cause cancer; they typically predispose an individual to cancer by reducing the number of somatic mutations required for tumorigenesis. For example, individuals carrying a germline mutation in *BRCA1* inherit one defective copy of this DNA repair gene in every cell. A somatic "second hit" that inactivates the remaining wild-type allele in a breast epithelial cell initiates tumor formation.

Somatic mutations, by contrast, arise spontaneously in individual cells during an individual's lifetime. They can result from errors during DNA replication, exposure to environmental mutagens such as ultraviolet radiation or tobacco smoke, or defective DNA repair. Somatic mutations are not inherited and are found only in the tumor tissue, not in normal tissues of the same individual. Understanding this distinction is critical for interpreting genetic testing results and for understanding the [genetic basis of cancer](/knowledge/molecular-biology/genetic-mutation) as a whole.

## Key Classes of Cancer Genes

Cancer genes fall into three broad functional categories: oncogenes, [tumor suppressor genes](/knowledge/molecular-biology/tumor-suppressor-gene), and DNA repair genes. Each class contributes to tumorigenesis through distinct mechanisms, and the nature of the mutations that activate or inactivate them reflects their normal physiological roles.

### Oncogenes and Gain-of-Function Mutations

Oncogenes are derived from normal cellular genes called proto-oncogenes, which promote cell proliferation, survival, or differentiation. Proto-oncogenes act as accelerators of cell growth. A gain-of-function mutation converts a proto-oncogene into an oncogene, resulting in a protein that is hyperactive, expressed at inappropriate times, or resistant to normal regulatory controls. Because oncogenes act dominantly, a single mutated allele is sufficient to promote cancer.

The mechanisms of oncogene activation include point mutations that alter protein function, gene amplification that increases protein levels, and chromosomal rearrangements that create fusion proteins or place the gene under the control of a constitutively active promoter. Classic examples include:

- **RAS family genes (*KRAS*, *NRAS*, *HRAS*)**: These encode small GTPases that cycle between active GTP-bound and inactive GDP-bound states. Point mutations at codons 12, 13, or 61 lock RAS in the active conformation, leading to constitutive activation of downstream signaling pathways such as the RAF-MEK-ERK cascade. *KRAS* mutations occur in approximately 90% of pancreatic ductal adenocarcinomas and 40% of colorectal cancers.
- **EGFR**: The epidermal growth factor receptor is a [receptor tyrosine kinase](/knowledge/molecular-biology/receptor-tyrosine-kinase). Mutations in the tyrosine kinase domain, such as the L858R point mutation or exon 19 deletions, cause ligand-independent activation. These mutations are found in a subset of non-small cell lung cancers and predict response to EGFR inhibitors.
- **BCR-ABL1**: This fusion gene results from the Philadelphia chromosome translocation t(9;22), which fuses the *BCR* gene on chromosome 22 with the *ABL1* gene on chromosome 9. The resulting BCR-ABL1 fusion protein has constitutive tyrosine kinase activity and drives chronic myeloid leukemia.

### Tumor Suppressors and Loss-of-Function

Tumor suppressor genes encode proteins that restrain cell proliferation, promote apoptosis, or maintain genomic integrity. They act as brakes on cell growth. In contrast to oncogenes, tumor suppressor genes are typically inactivated through loss-of-function mutations. Because most tumor suppressors follow the "two-hit hypothesis" proposed by Alfred Knudson, both alleles must be inactivated for the tumor-suppressive function to be lost. The first hit may be inherited (germline) or somatic, while the second hit is usually a somatic event such as a point mutation, loss of heterozygosity, or promoter hypermethylation.

Key tumor suppressors include:

- **TP53**: Encoding the p53 protein, this is the most frequently mutated gene in human cancer, with mutations in over 50% of tumors. p53 is a transcription factor that responds to cellular stress by inducing cell cycle arrest, DNA repair, or apoptosis. Loss of p53 function eliminates these critical checkpoints, allowing damaged cells to proliferate.
- **RB1**: The retinoblastoma protein regulates the G1/S cell cycle checkpoint by binding and inhibiting the E2F transcription factors. Loss of RB1 function leads to uncontrolled S-phase entry. Germline mutations in *RB1* cause hereditary retinoblastoma, and somatic inactivation occurs in many other cancers.
- **APC**: The adenomatous polyposis coli protein is a component of the β-catenin destruction complex. Loss of APC leads to stabilization of β-catenin and constitutive activation of the Wnt signaling pathway, driving intestinal cell proliferation. Germline *APC* mutations cause familial adenomatous polyposis, characterized by hundreds of colorectal polyps.

### DNA Repair Genes and Mutator Phenotype

DNA repair genes constitute a third class of cancer genes. Unlike oncogenes and tumor suppressors, which directly regulate cell growth, DNA repair genes maintain genomic stability. When these genes are inactivated, the rate of mutation across the entire genome increases, creating a "mutator phenotype" that accelerates the acquisition of oncogenic and tumor-suppressive mutations.

DNA repair pathways include [nucleotide excision repair](/knowledge/molecular-biology/nucleotide-excision-repair) (NER), base excision repair (BER), mismatch repair (MMR), and [homologous recombination](/knowledge/molecular-biology/homologous-recombination) repair (HRR). Defects in each pathway predispose to specific cancer types. For example:

- **Mismatch repair genes (*MLH1*, *MSH2*, *MSH6*, *PMS2*)**: These genes correct base-base mismatches and small insertion-deletion loops that arise during DNA replication. Loss of MMR function causes microsatellite instability—the expansion or contraction of short repetitive DNA sequences—and predisposes to Lynch syndrome, which carries a high risk of colorectal and endometrial cancer.
- **BRCA1 and BRCA2**: These genes are essential for [homologous recombination](/knowledge/molecular-biology/homologous-recombination) repair of DNA double-strand breaks. Cells lacking functional BRCA1 or BRCA2 rely on error-prone non-homologous end joining, leading to chromosomal rearrangements. Germline mutations in these genes confer a 60-80% lifetime risk of breast cancer and a 15-40% risk of ovarian cancer.

## Types of Mutations Driving Cancer

The mutations that drive cancer are diverse in scale, ranging from single nucleotide changes to whole-chromosome gains or losses. Understanding the types of mutations is essential for interpreting genomic data and for designing targeted therapies.

### Point Mutations and Their Effects

Point mutations are single nucleotide substitutions. In cancer, these can be:

- **Missense mutations**: Change one amino acid to another. The functional consequence depends on the location and nature of the substitution. For example, the *BRAF* V600E mutation substitutes valine with glutamic acid at position 600, constitutively activating the kinase domain.
- **Nonsense mutations**: Introduce a premature stop codon, leading to a truncated, usually non-functional protein. These frequently inactivate tumor suppressors.
- **Splice site mutations**: Alter RNA splicing, potentially producing aberrant proteins or causing exon skipping.
- **Silent mutations**: Do not change the amino acid sequence. These are usually passengers, though they can occasionally affect splicing or mRNA stability.

The mutational spectrum—the pattern of base substitutions—varies by cancer type and reflects the underlying mutagenic exposure. For example, melanomas show a predominance of C→T transitions at dipyrimidine sites, a signature of ultraviolet radiation damage, while lung cancers in smokers show a high burden of C→A transversions caused by polycyclic aromatic hydrocarbons in tobacco smoke.

### Chromosomal Translocations and Gene Fusions

Chromosomal translocations involve the exchange of genetic material between non-homologous chromosomes. When a translocation breaks a gene at the junction point and fuses it to another gene, the result is a fusion gene encoding a chimeric protein with novel properties. Translocations are particularly common in hematological malignancies and sarcomas.

Two mechanistic classes of translocations exist. In lymphoid malignancies, translocations often result from errors in V(D)J recombination or class switch recombination, placing an oncogene such as *MYC* or *BCL2* under the control of immunoglobulin or T-cell receptor enhancers. In other cancers, translocations create fusion proteins with constitutive activity. Examples include the *BCR-ABL1* fusion in chronic myeloid leukemia, the *EWSR1-FLI1* fusion in Ewing sarcoma, and the *TMPRSS2-ERG* fusion in prostate cancer. These fusion genes are often ideal therapeutic targets because they are tumor-specific and essential for cancer cell survival.

### Copy Number Changes and Aneuploidy

Copy number alterations (CNAs) are gains or losses of chromosomal segments. They can range from focal amplifications of a single oncogene to the loss of an entire chromosome. Gene amplification increases the copy number of an oncogene, leading to protein overexpression. Examples include *ERBB2* (HER2) amplification in breast cancer and *MYCN* amplification in neuroblastoma. Conversely, deletion of chromosomal regions containing tumor suppressor genes removes the remaining functional allele.

Aneuploidy—an abnormal chromosome number—is a hallmark of most solid tumors. The consequences of aneuploidy are complex: it can cause both gene dosage effects and genomic instability. The relationship between aneuploidy and cancer is bidirectional; aneuploidy promotes tumorigenesis, but the chromosomal instability that causes aneuploidy is itself driven by mutations in genes controlling mitosis, such as *BUB1B* or *AURKA*.

## Hallmarks of Cancer and Genetic Pathways

The genetic alterations described above do not act in isolation. They converge on a limited set of biological capabilities that collectively enable tumor growth and dissemination. These capabilities, termed the hallmarks of cancer, provide a framework for connecting specific mutations to the [molecular mechanism of cancer](/knowledge/molecular-biology/molecular-mechanism-of-cancer).

### Cell Cycle Dysregulation

The cell cycle is tightly regulated by [cyclin-dependent kinases](/knowledge/molecular-biology/cyclin-dependent-kinase) (CDKs) and their cyclin partners. The G1/S checkpoint, controlled by the RB1 pathway, is disrupted in the vast majority of cancers. This disruption can occur through:

1. Inactivation of *RB1* itself.
2. Overexpression of cyclin D1 (*CCND1*) or CDK4/6.
3. Loss of CDK inhibitors such as p16^INK4a (encoded by *CDKN2A*).
4. Activation of growth factor signaling pathways that drive cyclin expression.

The net effect is constitutive progression through the G1/S checkpoint, allowing cells to divide in the absence of mitogenic signals. CDK4/6 inhibitors such as palbociclib exploit this dependency and are used clinically in hormone receptor-positive breast cancer.

### Evasion of Apoptosis

Apoptosis, or programmed cell death, is a critical barrier to tumorigenesis. The p53 pathway is the primary sensor of cellular stress and DNA damage, and its loss eliminates the apoptotic response to these insults. Additionally, the BCL2 family of proteins regulates the mitochondrial (intrinsic) pathway of apoptosis. Overexpression of anti-apoptotic proteins such as BCL2, or loss of pro-apoptotic proteins such as BAX, allows cancer cells to survive conditions that would normally trigger cell death. The t(14;18) translocation in follicular lymphoma places *BCL2* under the control of the immunoglobulin heavy chain enhancer, leading to BCL2 overexpression and resistance to apoptosis.

### Angiogenesis and Metastasis

Tumors require a blood supply to grow beyond approximately 1-2 mm³. The transcription factor hypoxia-inducible factor 1α (HIF1α) is stabilized under low oxygen conditions and induces expression of vascular endothelial growth factor (VEGF), which stimulates angiogenesis. Mutations that activate the PI3K-AKT-mTOR pathway or inactivate the von Hippel-Lindau tumor suppressor (*VHL*) also promote angiogenesis through HIF1α stabilization.

Metastasis—the spread of cancer cells to distant organs—requires the acquisition of additional capabilities: invasion through the extracellular matrix, intravasation into blood or lymphatic vessels, survival in the circulation, extravasation, and colonization of distant tissues. The epithelial-mesenchymal transition (EMT) is a key program that enables these steps. Transcription factors such as SNAIL, SLUG, and ZEB1 repress epithelial markers (E-cadherin) and induce mesenchymal markers (vimentin, N-cadherin), conferring migratory and invasive properties. Mutations in *TP53*, *KRAS*, and *SMAD4* can promote EMT, as can signals from the tumor microenvironment.

## Methods to Study Cancer Genetics

Identifying the mutations that drive cancer requires a suite of molecular and cytogenetic techniques. These methods have evolved from low-throughput, single-gene analyses to genome-wide approaches that can characterize the entire mutational landscape of a tumor.

### Next-Generation Sequencing

Next-generation sequencing (NGS) has revolutionized cancer genetics by enabling the parallel sequencing of millions of DNA fragments. Three main applications are relevant:

- **Whole-genome sequencing (WGS)**: Determines the complete DNA sequence of a tumor genome, revealing point mutations, structural variants, and copy number changes. WGS is expensive and computationally intensive but provides the most comprehensive view.
- **Whole-exome sequencing (WES)**: Sequences only the protein-coding regions (approximately 1-2% of the genome). WES is more cost-effective than WGS and captures most driver mutations, as the majority of known cancer genes are protein-coding.
- **Targeted gene panels**: Sequence a defined set of cancer-related genes (typically 50-500 genes). These panels are used clinically for diagnosis, prognosis, and treatment selection. For example, the FoundationOne CDx panel sequences 324 genes and reports [tumor mutational burden](/knowledge/bioinformatics/tumor-mutational-burden-tmb-and-computational-scoring) and microsatellite instability status.

A typical NGS workflow involves: DNA extraction from tumor and matched normal tissue, library preparation (fragmentation, end-repair, adapter ligation, and PCR amplification), sequencing on platforms such as Illumina or Ion Torrent, and bioinformatic analysis to identify variants. Sequencing depth—the average number of times each base is read—typically ranges from 100× to 1000× for clinical panels, with higher depth improving sensitivity for low-frequency variants.

### Cytogenetics and FISH

Cytogenetic techniques visualize chromosomes and chromosomal abnormalities. Conventional karyotyping requires dividing cells, which are arrested in metaphase, stained with Giemsa (G-banding), and examined under a microscope. This technique can detect translocations, deletions, and aneuploidy at a resolution of approximately 5-10 megabases.

Fluorescence [in situ hybridization](/knowledge/molecular-biology/in-situ-hybridization) (FISH) uses fluorescently labeled DNA probes that hybridize to specific chromosomal regions. FISH can detect gene amplifications (e.g., *ERBB2* in breast cancer), deletions (e.g., *TP53* in chronic lymphocytic leukemia), and translocations (e.g., *BCR-ABL1* in chronic myeloid leukemia) in both dividing and non-dividing cells. FISH is faster and more sensitive than karyotyping but only examines the specific loci targeted by the probes.

### Functional Assays and Model Systems

Identifying a mutation is not sufficient to prove it drives cancer; functional validation is required. Several model systems are used:

- **Cell lines**: Cancer cell lines can be genetically manipulated using CRISPR-Cas9 to introduce or correct mutations, then assayed for proliferation, invasion, or drug sensitivity.
- **Organoids**: Three-dimensional cultures derived from patient tumors or normal tissues that recapitulate tissue architecture. Organoids can be used to test drug responses and study tumor biology in a more physiologically relevant context.
- **Patient-derived xenografts (PDX)**: Tumor tissue implanted into immunodeficient mice. PDX models preserve the genetic and histological features of the original tumor and are used for drug testing and biomarker discovery.
- **Genetically engineered mouse models (GEMMs)**: Mice carrying specific mutations (e.g., *Kras^LSL-G12D*; *Trp53^fl/fl*) that develop tumors recapitulating human disease. GEMMs allow study of tumor initiation, progression, and response to therapy in an intact immune system.

## Evidence Linking Genetics to Cancer

The evidence that cancer is a genetic disease comes from multiple lines of investigation, ranging from familial studies to large-scale genomics projects.

### Familial Cancer Syndromes

Familial cancer syndromes provide the strongest evidence for the heritability of cancer predisposition. These syndromes follow Mendelian inheritance patterns and are caused by germline mutations in specific genes. Examples include:

| Syndrome | Gene | Inheritance | Associated Cancers |
|----------|------|-------------|-------------------|
| Hereditary breast and ovarian cancer | *BRCA1*, *BRCA2* | Autosomal dominant | Breast, ovarian, pancreatic, prostate |
| Lynch syndrome | *MLH1*, *MSH2*, *MSH6*, *PMS2* | Autosomal dominant | Colorectal, endometrial, ovarian, gastric |
| Familial adenomatous polyposis | *APC* | Autosomal dominant | Colorectal (hundreds of polyps) |
| Li-Fraumeni syndrome | *TP53* | Autosomal dominant | Sarcomas, breast, brain, adrenal |
| Retinoblastoma | *RB1* | Autosomal dominant | Retinal tumors in children |
| von Hippel-Lindau disease | *VHL* | Autosomal dominant | Renal cell carcinoma, hemangioblastoma |

The study of these syndromes has been instrumental in identifying the underlying genes. Knudson's analysis of retinoblastoma—showing that hereditary cases develop tumors earlier and bilaterally, while sporadic cases develop later and unilaterally—led to the two-hit hypothesis and the identification of *RB1*.

### Cancer Genome Atlas and Mutation Signatures

The Cancer Genome Atlas (TCGA) project, completed in 2018, profiled over 20,000 primary tumors across 33 cancer types using WES, RNA sequencing, DNA methylation arrays, and proteomics. TCGA revealed the extraordinary heterogeneity of cancer genomes: each tumor type has a characteristic set of frequently mutated genes, but no two tumors are identical. TCGA also identified novel driver genes and defined molecular subtypes within histologically similar tumors, with implications for treatment selection.

Mutation signature analysis examines the patterns of base substitutions in a tumor genome to infer the underlying mutational processes. For example, signature 1 is associated with spontaneous deamination of 5-methylcytosine and correlates with age; signature 4 is associated with tobacco smoking; and signature 6 is associated with defective DNA mismatch repair. These signatures can reveal environmental exposures, DNA repair defects, and even prior chemotherapy exposure, providing insight into the etiology of individual tumors.

## The Role of Genomic Instability and Tumor Evolution

Genomic instability—an elevated rate of mutation or chromosomal alteration—is a hallmark of cancer that fuels tumor heterogeneity and evolution. Without instability, the accumulation of the multiple mutations required for tumorigenesis would be too slow to occur within a human lifetime.

### Mechanisms of Genomic Instability

Several mechanisms contribute to genomic instability:

- **Defective DNA repair**: As discussed, mutations in MMR or HRR genes increase the mutation rate. Cells with defective MMR have a mutation rate 100-1000 times higher than normal cells.
- **Chromosomal instability (CIN)**: The continuous gain or loss of whole chromosomes or large chromosomal segments. CIN can result from defects in the mitotic spindle checkpoint, sister chromatid cohesion, or centrosome duplication. The resulting aneuploidy alters gene dosage and can drive tumor progression.
- **Telomere dysfunction**: Telomeres are repetitive DNA sequences at chromosome ends that shorten with each cell division. When telomeres become critically short, they trigger a DNA damage response and cell cycle arrest. Tumors that escape this arrest through inactivation of *TP53* or *RB1* may enter crisis, characterized by end-to-end chromosome fusions and massive genomic rearrangement.
- **Defects in replication fidelity**: Mutations in DNA polymerase genes, such as *POLE* and *POLD1*, increase the error rate during DNA replication. Tumors with *POLE* mutations have extremely high mutation burdens (hypermutation) and are associated with favorable prognosis, likely because the high neoantigen load triggers a strong immune response.

### Clonal Evolution and Resistance

Tumors are not static entities; they evolve continuously. The process of clonal evolution begins with a single initiating cell and proceeds through successive rounds of mutation, selection, and expansion. The result is a heterogeneous tumor containing multiple subclones with different genetic alterations.

This heterogeneity has profound therapeutic implications. When a targeted therapy is administered, it kills sensitive subclones but selects for resistant ones that pre-exist or arise during treatment. For example, in chronic myeloid leukemia treated with imatinib, resistance often arises through point mutations in the *BCR-ABL1* kinase domain that prevent drug binding. Similarly, in non-small cell lung cancer treated with EGFR inhibitors, resistance can emerge through the T790M mutation in *EGFR* or through activation of bypass signaling pathways such as *MET* amplification.

Understanding clonal evolution has led to the concept of "trunk" versus "branch" mutations. Trunk mutations are present in all tumor cells and occur early in tumorigenesis; they are attractive therapeutic targets because targeting them should kill all tumor cells. Branch mutations are present in only a subset of cells and are responsible for intratumoral heterogeneity and resistance.

## Therapeutic Implications of Cancer Genetics

The genetic characterization of tumors has transformed cancer treatment from a one-size-fits-all approach to precision medicine, where therapy is selected based on the specific genetic alterations in a patient's tumor.

### Targeted Therapies and Oncogene Addiction

Many cancers depend on the continued activity of a single oncogene for their survival and proliferation—a phenomenon called oncogene addiction. This dependency creates an Achilles' heel that can be exploited therapeutically. Targeted therapies are designed to inhibit the products of specific oncogenes or the signaling pathways they activate.

Examples include:

- **Imatinib** for *BCR-ABL1*-positive chronic myeloid leukemia. Imatinib is a small-molecule inhibitor of the BCR-ABL1 tyrosine kinase. It induces complete cytogenetic remission in over 80% of patients in chronic phase.
- **Trastuzumab** for *ERBB2*-amplified breast cancer. Trastuzumab is a monoclonal antibody that binds the HER2 receptor, blocking signaling and triggering antibody-dependent cellular cytotoxicity.
- **Vemurafenib** for *BRAF* V600E-mutant melanoma. Vemurafenib selectively inhibits the mutant BRAF kinase, producing response rates of approximately 50% in metastatic melanoma.
- **Osimertinib** for *EGFR*-mutant non-small cell lung cancer, including tumors with the T790M resistance mutation. Osimertinib is a third-generation EGFR inhibitor that covalently binds the kinase domain.

The success of these therapies depends on accurate genetic testing. Molecular pathology laboratories use targeted NGS panels to identify actionable mutations, and the results guide treatment selection. The [molecular cancer diagnosis](/knowledge/molecular-biology/molecular-cancer-diagnosis) workflow typically involves tissue biopsy, DNA extraction, sequencing, and bioinformatic interpretation, with a turnaround time of 7-14 days.

### Synthetic Lethality and DNA Repair Defects

Synthetic lethality refers to a situation where mutations in two genes are lethal only when both are inactivated, while mutation of either gene alone is viable. This concept has been exploited therapeutically in cancers with defective homologous recombination repair.

PARP inhibitors (e.g., olaparib, niraparib) exploit synthetic lethality in *BRCA1*- or *BRCA2*-mutant tumors. PARP (poly-ADP ribose polymerase) is involved in base excision repair of single-strand breaks. When PARP is inhibited, single-strand breaks persist and are converted to double-strand breaks during DNA replication. In normal cells, these double-strand breaks are repaired by homologous recombination. In *BRCA*-deficient cells, homologous recombination is defective, so the double-strand breaks are repaired by error-prone non-homologous end joining, leading to genomic catastrophe and cell death. PARP inhibitors are now standard therapy for *BRCA*-mutant ovarian and breast cancers.

The success of PARP inhibitors has stimulated interest in identifying other synthetic lethal interactions. For example, *ARID1A*-mutant cancers are sensitive to inhibitors of the ATR kinase, and *SMARCA4*-mutant cancers may be sensitive to inhibitors of the EZH2 methyltransferase.

## Common Pitfalls in Understanding Cancer Genetics

Students frequently encounter several conceptual difficulties when studying the genetic basis of cancer. Recognizing these pitfalls is essential for mastering the material.

### Misconceptions About Inherited vs. Somatic Mutations

A common error is to assume that because cancer is a genetic disease, it must be inherited. In fact, the vast majority of cancer mutations are somatic—they arise in individual cells during a person's lifetime and are not passed to offspring. Only 5-10% of cancers occur in the context of a clearly inherited germline mutation. Furthermore, even in hereditary cancer syndromes, the germline mutation is a predisposition, not a guarantee; additional somatic mutations are required for tumor formation.

Another misconception is that all cells in a tumor share the same mutations. In reality, tumors are heterogeneous, with different subclones harboring different mutations. This heterogeneity arises through clonal evolution and has major implications for treatment resistance.

### Distinguishing Driver vs. Passenger Mutations

Students often assume that every mutation found in a cancer genome is important. In fact, the majority of mutations in a typical tumor are passengers—they occurred incidentally during cell division and do not contribute to tumorigenesis. Only a small number of mutations are drivers that confer a selective growth advantage.

Distinguishing drivers from passengers requires multiple lines of evidence:

1. **Frequency**: Driver genes are mutated more frequently than expected by chance across tumors of a given type.
2. **Functional impact**: Driver mutations typically alter protein function in ways that promote cancer (e.g., activating oncogenes, inactivating tumor suppressors).
3. **Recurrence**: Driver mutations tend to occur at the same amino acid positions (e.g., *KRAS* codons 12, 13, 61) or in the same functional domains.
4. **Experimental validation**: Functional assays in cell lines or animal models confirm that the mutation promotes tumorigenesis.

A related pitfall is assuming that a mutation in a known cancer gene is always a driver. Context matters: a *TP53* mutation in a tumor with high mutation burden might be a passenger if it does not affect p53 function. Conversely, a mutation in a gene not previously linked to cancer could be a driver if it provides a selective advantage.

## Frequently Asked Questions

### What is the genetic basis of cancer?

The genetic basis of cancer refers to the accumulation of mutations in somatic cells that confer a selective growth advantage, leading to uncontrolled proliferation, invasion, and metastasis. These mutations affect three main classes of genes: oncogenes (gain-of-function), tumor suppressor genes (loss-of-function), and DNA repair genes (loss of function leading to genomic instability). Cancer arises through a multistep process of clonal evolution, where successive mutations and selection produce increasingly aggressive tumors.

### Are all cancers caused by genetic mutations?

Yes, all cancers are caused by genetic mutations, but the term "genetic" here refers to somatic mutations in tumor cells, not inherited mutations. Every cancer contains somatic mutations in its genome, and these mutations are necessary for tumor initiation and progression. However, only a minority of cancers are caused by inherited germline mutations. Environmental factors such as tobacco smoke, ultraviolet radiation, and certain viruses cause cancer by inducing somatic mutations.

### What are oncogenes and tumor suppressor genes?

Oncogenes are mutated forms of proto-oncogenes that promote cell proliferation. They act dominantly, meaning a single mutated allele is sufficient to contribute to cancer. Examples include *KRAS*, *EGFR*, and *MYC*. Tumor suppressor genes normally restrain cell growth and promote apoptosis. They act recessively, requiring inactivation of both alleles for loss of function. Examples include *TP53*, *RB1*, and *APC*. The distinction is important because oncogenes are activated by gain-of-function mutations, while tumor suppressors are inactivated by loss-of-function mutations.

### How do mutations in DNA repair genes cause cancer?

Mutations in DNA repair genes do not directly promote cell proliferation; instead, they increase the mutation rate across the genome, creating a mutator phenotype. This elevated mutation rate accelerates the acquisition of mutations in oncogenes and tumor suppressor genes, thereby promoting tumorigenesis. Examples include mismatch repair genes (*MLH1*, *MSH2*) in Lynch syndrome and homologous recombination genes (*BRCA1*, *BRCA2*) in hereditary breast and ovarian cancer.

### What is the difference between driver and passenger mutations?

Driver mutations confer a selective growth advantage and are causally implicated in tumorigenesis. They occur in cancer genes and are positively selected during clonal evolution. Passenger mutations are incidental alterations that do not contribute to cancer development; they arise because of the general increase in mutation rate or because they are linked to driver mutations on the same chromosome. A typical tumor contains 30-100 non-silent mutations, but only 2-8 are drivers.

### Can cancer be inherited?

Cancer itself is not inherited, but genetic predisposition to cancer can be. Germline mutations in genes such as *BRCA1*, *BRCA2*, *TP53*, and *APC* are passed from parent to child and increase the risk of developing specific cancers. However, these germline mutations are not sufficient to cause cancer; additional somatic mutations are required. Individuals with such mutations may benefit from enhanced surveillance, risk-reducing surgery, or chemoprevention, as discussed in [A Guide to Genetic Counseling](/knowledge/molecular-biology/a-guide-to-genetic-counseling).

### How do genetic changes lead to cancer hallmarks?

Genetic changes in oncogenes, tumor suppressors, and DNA repair genes collectively enable the hallmarks of cancer: sustained proliferative signaling, evasion of growth suppressors, resistance to cell death, replicative immortality, induction of angiogenesis, and activation of invasion and metastasis. For example, *KRAS* mutations drive sustained proliferation, *TP53* loss disables apoptosis and growth arrest, and *VHL* loss promotes angiogenesis. Each hallmark is supported by multiple genetic alterations, reflecting the redundancy and robustness of cancer pathways.

### What methods are used to identify cancer genes?

Cancer genes are identified through a combination of approaches. Next-generation sequencing (whole-genome, whole-exome, or targeted panels) identifies mutations in tumor samples. Statistical analyses compare mutation frequencies to identify genes mutated more often than expected by chance. Functional assays using CRISPR-Cas9, RNA interference, or small-molecule inhibitors validate the role of candidate genes in tumorigenesis. Cytogenetic techniques such as karyotyping and FISH detect chromosomal abnormalities. Model systems including cell lines, organoids, and genetically engineered mice provide experimental evidence for causality.

## Key Takeaways

- Cancer is a genetic disease caused by the accumulation of somatic mutations that confer a selective growth advantage, driving clonal evolution and tumor progression.
- Three classes of cancer genes exist: oncogenes (activated by gain-of-function mutations), tumor suppressor genes (inactivated by loss-of-function mutations), and DNA repair genes (inactivated, leading to genomic instability).
- Driver mutations actively promote cancer, while passenger mutations are incidental; distinguishing them requires frequency, functional, and experimental evidence.
- The hallmarks of cancer—sustained proliferation, evasion of apoptosis, angiogenesis, and metastasis—are enabled by specific genetic alterations converging on key signaling pathways.
- Genomic instability accelerates mutation accumulation and drives intratumoral heterogeneity, which underlies therapeutic resistance.
- Genetic characterization of tumors enables precision medicine, including targeted therapies (e.g., imatinib, trastuzumab) and synthetic lethal approaches (e.g., PARP inhibitors in *BRCA*-mutant cancers).
- Understanding the distinction between inherited and somatic mutations, and between drivers and passengers, is essential for interpreting cancer genomics and for clinical decision-making.

## Further Reading

- Linehan WM et al. *The Metabolic Basis of Kidney Cancer*. Cancer discovery. 2019. [PubMed 31088840](https://doi.org/10.1158/2159-8290.CD-18-1354)
- Bicknell LS, Hirschhorn JN, Savarirayan R. *The genetic basis of human height*. Nature reviews. Genetics. 2025. [PubMed 40189669](https://doi.org/10.1038/s41576-025-00834-1)
- Butera A, Melino G, Amelio I. *Epigenetic "Drivers" of Cancer*. Journal of molecular biology. 2021. [PubMed 34119490](https://doi.org/10.1016/j.jmb.2021.167094)
- PCAWG Transcriptome Core Group et al. *Genomic basis for RNA alterations in cancer*. Nature. 2020. [PubMed 32025019](https://doi.org/10.1038/s41586-020-1970-0)
- D'Asti E et al. *Genetic basis of thrombosis in cancer*. Seminars in thrombosis and hemostasis. 2014. [PubMed 24599437](https://doi.org/10.1055/s-0034-1370766)
- Ahmad A et al. *Epigenetic basis of cancer health disparities: Looking beyond genetic differences*. Biochimica et biophysica acta. Reviews on cancer. 2017. [PubMed 28108348](https://doi.org/10.1016/j.bbcan.2017.01.001)

## Related Clinical & Scientific Guides

* [MAPK Pathway: Mechanism, Function, and Clinical Relevance](/knowledge/molecular-biology/mapk-pathway)
* [Mammalian Cell Culture Bioreactors: A Practical Guide](/knowledge/molecular-biology/mammalian-cell-culture-bioreactor)
* [Nucleotide Formation: Biosynthesis and Assembly of DNA/RNA Building Blocks](/knowledge/molecular-biology/nucleotide-formation)